Autopsy report · NCT00322036
Global Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's
Cause of deathFunding or business
“Myriad has discontinued the development of Flurizan.”
Life of this trial
- Ran for about 2 years 7 months before it stopped.
- 800 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- Myrexis Inc.
- Sponsor type
- Industry
- Conditions
- Alzheimer Disease; Dementia
- Interventions
- MPC-7869; MPC-7869
- Participants
- 800
- Sites
- 92
- Countries
- Belgium, Canada, Denmark, France, Germany, Italy, Netherlands, Spain, Sweden, Switzerland, United Kingdom, United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.